LL-37 vs Thymogen
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cathelicidin, CAP18
LL-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hCAP-18. It is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. This is mainstream, heavily studied human biology, not a fringe research peptide, though LL-37 itself is not an approved drug.
Also: EW Dipeptide, Glu-Trp
Thymogen is the brand name for L-Glu-L-Trp (glutamyl-tryptophan, the dipeptide EW), an immune-modulating peptide isolated from the calf thymus extract Thymalin. It is the smallest active piece of that thymic complex and is studied for boosting T-cell activity and immune function. It has been used clinically in Russia since 1990 but has never been evaluated or approved by any Western regulator, and rigorous independent trials are lacking.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
Detailed Comparison
| Attribute | LL-37 | Thymogen |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | LL-37 carries a net positive charge and has a water-loving and fat-loving (amphipathic) structure, which lets it home in on the negatively charged membranes of bacteria and physically punch holes in them. But killing microbes directly is only half the job. It also acts as a signaling molecule: it neutralizes bacterial toxin LPS, calms or tunes the inflammatory response, recruits immune cells to wounds and infection sites, and helps skin re-grow and close over injuries. It is produced by skin, gut, lung, and other epithelial cells, plus immune cells like neutrophils. This dual role, direct antimicrobial plus immune coordinator, is why it is described as a multifunctional host-defense peptide. | Thymogen is meant to mimic what thymus-derived peptides do to the immune system. In experiments it has been reported to push T-cell differentiation, improve T-cell recognition of peptide-MHC complexes, shift the balance of intracellular cyclic nucleotides, and ramp up neutrophil chemotaxis and phagocytosis. In plain terms, it is proposed to wake up parts of the immune defense, especially in states where immunity is run down. Like other Khavinson peptides, it has also been described as influencing gene expression at the level of DNA, though the immunomodulatory effects are the better-documented part of its story. The exact molecular trigger that starts these effects is not fully pinned down. |
| Common Dosing | 100-200 mcg daily Once daily | 1-2 capsules (10-20 mg) daily 1-2x daily, before meals |
| Administration | Subcutaneous injection or topical | Oral capsules, also available as nasal spray in some regions |
| Typical Duration | Variable by protocol | 30-day courses with 2-3 month breaks |
| Best Time to Take | Morning | Morning, before meals |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The basic biology of LL-37 is well established across many peer-reviewed studies. Its broad antimicrobial activity, membrane-disrupting mechanism, and tissue distribution are documented in reviews such as those in the Journal of Leukocyte Biology and PMC-indexed updates on how it limits the spread of local infection. Research has also explored more speculative directions: LL-37 and engineered mimics have shown anticancer activity in laboratory models, and it has been studied as a possible host-defense factor against Helicobacter pylori in the stomach and against pathogens on the surface of the eye. The important honesty point is that almost all of this is mechanistic and preclinical. LL-37 is firmly proven as a natural part of human immunity, but as a deliberately administered therapy it has not cleared large human clinical trials, and its dual nature means it can also drive inflammation in some disease states. So: rock-solid as biology, still experimental as a treatment. | The most-cited international study is Anisimov and colleagues in Biogerontology (2000), where the dipeptide was given to rats and was associated with a longer maximum lifespan and markedly lower tumor incidence, including a roughly 3.4-fold drop in blood cancers versus controls. That is an animal study, not a human trial. A large body of supporting clinical and laboratory data exists, but it is overwhelmingly Russian-language, older, and produced by groups connected to the original developers, with little independent Western replication. There are no modern randomized controlled trials by outside labs confirming the immune or anti-aging claims to current evidence standards. So the fair summary is: decades of use and a real animal signal for immune and anti-tumor effects, but the high-quality, independently verified human evidence that Western medicine would want is simply not there. |
Frequently Asked Questions: LL-37 vs Thymogen
What is the difference between LL-37 and Thymogen?
LL-37 is a immune peptide that ll-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hcap-18. it is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. this is mainstream, heavily studied human biology, not a fringe research peptide, though ll-37 itself is not an approved drug. Thymogen is a immune peptide that thymogen is the brand name for l-glu-l-trp (glutamyl-tryptophan, the dipeptide ew), an immune-modulating peptide isolated from the calf thymus extract thymalin. it is the smallest active piece of that thymic complex and is studied for boosting t-cell activity and immune function. it has been used clinically in russia since 1990 but has never been evaluated or approved by any western regulator, and rigorous independent trials are lacking. The main differences lie in their mechanisms of action and clinical applications.
Which is better, LL-37 or Thymogen?
Neither is universally "better" - the choice depends on your specific goals. LL-37 is typically used for immune purposes, while Thymogen is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can LL-37 and Thymogen be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using LL-37 and Thymogen together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.